A. Patterson

发表

Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma

W. Wilson, S. Jamieson, M. Abbattista, 2015, Cancer biology & therapy.

Bystander or No Bystander for Gene Directed Enzyme Prodrug Therapy

D. Singleton, G. Dachs, A. Patterson, 2009, Molecules.

O. Greco, A. Patterson, M. Saunders, 2003, Current pharmaceutical design.

Optimized clostridium-directed enzyme prodrug therapy improves the antitumor activity of the novel DNA cross-linking agent PR-104.

J. Brown, G. Ahn, M. Dorie, 2008, Cancer research.

Thymidine phosphorylase moderates thymidine-dependent rescue after exposure to the thymidylate synthase inhibitor ZD1694 (Tomudex) in vitro.

A. Harris, D. Talbot, I. Stratford, 1998, Cancer research.

Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506

P. Lambin, L. Dubois, A. Jochems, 2021, Molecular Cancer Therapeutics.

Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase.

A. Harris, D. Talbot, I. Stratford, 1995, British Journal of Cancer.

Diflavin Oxidoreductases Activate the Bioreductive Prodrug PR-104A under Hypoxia

W. Wilson, J. Su, G. Dachs, 2012, Molecular Pharmacology.

Evaluating the abilities of diverse nitroaromatic prodrug metabolites to exit a model Gram negative vector for bacterial‐directed enzyme‐prodrug therapy

J. Smaill, J. Copp, D. Ackerley, 2018, Biochemical pharmacology.

Creation and screening of a multi-family bacterial oxidoreductase library to discover novel nitroreductases that efficiently activate the bioreductive prodrugs CB1954 and PR-104A.

W. Denny, J. Smaill, G. Prosser, 2013, Biochemical pharmacology.

Pharmacological and biological evaluation of a series of substituted 1,4-naphthoquinone bioreductive drugs.

I. Stratford, P. Cooper, P. Loadman, 2004, Biochemical pharmacology.

Interrogation of the Structure–Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications

J. Smaill, J. Copp, D. Ackerley, 2022, Pharmaceuticals.

Targeting Tumor Hypoxia with Prodrugs: Challenges and Opportunities

W. Wilson, K. Hicks, F. Pruijn, 2008 .

Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed.

J. Smaill, J. Flanagan, M. McKeage, 2015, Journal of structural biology.

Dual responsive promoters to target therapeutic gene expression to radiation-resistant hypoxic tumor cells.

I. Stratford, K. Williams, S. Scott, 2005, International journal of radiation oncology, biology, physics.

Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects.

J. Smaill, Xiaoyun Lu, A. Patterson, 2018, Journal of medicinal chemistry.

Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3

J. Smaill, G. Prosser, G. Dachs, 2021, Pharmaceuticals.

The Flavin Reductase MsuE Is a Novel Nitroreductase that Can Efficiently Activate Two Promising Next-Generation Prodrugs for Gene-Directed Enzyme Prodrug Therapy

J. Smaill, J. Copp, D. Ackerley, 2013, Cancers.

Single agent‐ and combination treatment with two targeted suicide gene therapy systems is effective in chemoresistant small cell lung cancer cells

M. Sehested, C. Christensen, T. T. Poulsen, 2012, The journal of gene medicine.

Prototyping kinase inhibitor-cytotoxin anticancer mutual prodrugs activated by tumour hypoxia: A chemical proof of concept study.

J. Smaill, R. Anderson, M. Kelso, 2019, Bioorganic & medicinal chemistry letters.

Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506

P. Lambin, L. Dubois, A. Jochems, 2021, Molecular Cancer Therapeutics.

Improved Strategy for the Synthesis of the Anticancer Agent Culicinin D

J. Smaill, Sung‐Hyun Yang, M. Brimble, 2015 .

Discovery of Isoform-Selective Akt3 Degraders Overcoming Osimertinib-Induced Resistance in Non-Small Cell Lung Cancer Cells.

J. Smaill, Liang Chen, A. Patterson, 2022, Journal of medicinal chemistry.

The 1.65 Å resolution structure of the complex of AZD4547 with the kinase domain of FGFR1 displays exquisite molecular recognition.

J. Smaill, A. Patterson, Y. Yosaatmadja, 2015, Acta crystallographica. Section D, Biological crystallography.

Abstract 453: Identification of human oxidoreductases involved in the hypoxia-dependent activation of bioreductive prodrugs

W. Wilson, G. Dachs, M. Abbattista, 2010 .

Abstract B76: Cellular metabolism, murine pharmacokinetics and preclinical antitumor activity of SN29966, a novel hypoxia‐activated irreversible pan‐HER inhibitor

W. Denny, W. Wilson, F. Doñate, 2009 .

Investigation of Covalent Warheads in the Design of 2-Aminopyrimidine-based FGFR4 Inhibitors.

J. Smaill, Yongheng Chen, Xiaoyun Lu, 2021, ACS medicinal chemistry letters.

Synthesis and antiproliferative activity of C- and N-terminal analogues of culicinin D.

J. Smaill, M. Brimble, P. Harris, 2020, Bioorganic & medicinal chemistry letters.

Advancing Clostridia to Clinical Trial: Past Lessons and Recent Progress

P. Lambin, L. Dubois, J. Smaill, 2016, Cancers.

Viral delivery of P450 reductase recapitulates the ability of constitutive overexpression of reductase enzymes to potentiate the activity of mitomycin C in human breast cancer xenografts.

R. Airley, B. Telfer, I. Stratford, 2003, Molecular cancer therapeutics.

Antiangiogenic, bioreductive and gene therapy approaches to the treatment of hypoxic tumours.

I. Stratford, K. Williams, M. Jaffar, 2002, Current pharmaceutical design.

Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha

A. Harris, K. O'Byrne, T. Ganesan, 2000, British Journal of Cancer.

Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954.

W. Wilson, J. Smaill, G. Prosser, 2010, Biochemical pharmacology.

3-substituted-5-aziridinyl-1-methylindole-4,7-diones as NQO1-directed antitumour agents: mechanism of activation and cytotoxicity in vitro.

T. Ward, I. Stratford, K. Williams, 2003, Biochemical pharmacology.

Synthesis and cytotoxicity of pyranonaphthoquinone natural product analogues under bioreductive conditions.

J. Smaill, M. Brimble, S. Jamieson, 2013, Bioorganic & medicinal chemistry.

2,4-Diarylamino-pyrimidines as kinase inhibitors co-targeting IGF1R and EGFR(L⁸⁵⁸R/T⁷⁹⁰M).

J. Smaill, Jian Ding, Lin-jiang Tong, 2015, Bioorganic & medicinal chemistry letters.

DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamine.

S. Gamage, W. Denny, W. Wilson, 2004, Journal of medicinal chemistry.

N-(3-Ethynyl-2,4-difluorophenyl)sulfonamide Derivatives as Selective Raf Inhibitors.

Yong Xu, J. Smaill, Donghai Wu, 2015, ACS medicinal chemistry letters.

Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069.

A. Harris, D. Talbot, E. Chinje, 1997, British Journal of Cancer.

2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors.

Yong Xu, J. Smaill, Xiaoyun Lu, 2017, ACS medicinal chemistry letters.

A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors

W. Denny, W. Wilson, J. Gutheil, 2010, Cancer Chemotherapy and Pharmacology.

2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT

W. Wilson, N. Helsby, S. Pullen, 2004, British Journal of Cancer.

Zinc Finger Nuclease Knock-out of NADPH:Cytochrome P450 Oxidoreductase (POR) in Human Tumor Cell Lines Demonstrates That Hypoxia-activated Prodrugs Differ in POR Dependence*

W. Wilson, J. Smaill, F. Pruijn, 2013, The Journal of Biological Chemistry.

Effect of POR knockout on hypoxic prodrug activation

W. Wilson, J. Smaill, F. Pruijn, 2013 .

Rational enzyme-directed prodrug development : exploiting tumour hypoxia to target the bioactivation of cytotoxic prodrugs

A. Patterson, 1998 .

Use of an optimised enzyme/prodrug combination for Clostridia directed enzyme prodrug therapy induces a significant growth delay in necrotic tumours

P. Lambin, L. Dubois, J. Smaill, 2021, Cancer Gene Therapy.

E. coli nitroreductase NfsA is a reporter gene for non-invasive PET imaging in cancer gene therapy applications

P. Lambin, L. Dubois, J. Smaill, 2020, Theranostics.

Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy.

J. Smaill, J. Flanagan, J. Copp, 2016, Biochemical pharmacology.

Rational design of an AKR 1 C 3-resistant analog of PR-104 for enzyme-prodrug therapy

J. Smaill, J. Flanagan, J. Copp, 2016 .

Characterisation of enzyme prodrug gene therapy combinations in coated spheroids and vascular networks in vitro

M. Currie, G. Dachs, Dan Li, 2012, The journal of gene medicine.

The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411NTR

W. Denny, W. Wilson, J. Smaill, 2007, Cancer Gene Therapy.

Nitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utility.

J. Smaill, J. Copp, M. Rich, 2015, The Biochemical journal.

Molecular Chemotherapy for Breast Cancer

A. Harris, A. Patterson, 1999, Drugs & aging.

Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes

Chul Kim, R. Doebele, J. Smaill, 2020, Clinical Cancer Research.

The bioreductive agent RH1 and gamma-irradiation both cause G2/M cell cycle phase arrest and polyploidy in a p53-mutated human breast cancer cell line.

J. Hendry, I. Stratford, A. Patterson, 2004, International journal of radiation oncology, biology, physics.

The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3.

Rachelle S. Singleton, S. Fox, W. Wilson, 2010, Cancer research.

Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy

J. Smaill, I. Hermans, A. Patterson, 2021, Cells.

Targeting gene expression to hypoxic tumor cells

Adrian L. Harris, John D. Firth, A. Harris, 1997, Nature Medicine.

Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302

P. Glazer, R. Anderson, F. Meng, 2011, Molecular Cancer Therapeutics.

Identification of one-electron reductases that activate both the hypoxia prodrug SN30000 and diagnostic probe EF5.

W. Wilson, G. Dachs, A. Patterson, 2014, Biochemical pharmacology.

TAS-120 cancer target binding; defining reactivity and revealing the first FGFR1 irreversible structure.

J. Smaill, M. Middleditch, A. Patterson, 2019 .

TAS‐120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure

J. Smaill, M. Middleditch, A. Patterson, 2019, ChemMedChem.

2-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors.

Yong Xu, J. Smaill, Xiaoyun Lu, 2017, European journal of medicinal chemistry.

Design, Synthesis, and Biological Evaluation of 5-Formyl-pyrrolo[3,2-b]pyridine-3-carboxamides as New Selective, Potent, and Reversible-Covalent FGFR4 Inhibitors.

J. Smaill, Zheng-chao Tu, A. Patterson, 2022, Journal of medicinal chemistry.

Rotational Freedom, Steric Hindrance, and Protein Dynamics Explain BLU554 Selectivity for the Hinge Cysteine of FGFR4.

J. Smaill, Xiaoyun Lu, M. Middleditch, 2019, ACS medicinal chemistry letters.

Human NADPH-cytochrome p450 reductase overexpression does not enhance the aerobic cytotoxicity of doxorubicin in human breast cancer cell lines.

A. Patterson, Chunja Lee, D. S. Riddick, 2003, Cancer research.

Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors.

J. Smaill, Xiaoyun Lu, A. Patterson, 2021, Journal of medicinal chemistry.

Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia.

W. Wilson, A. Wang, A. Theil, 2007, Biochemical pharmacology.

Engineering a Multifunctional Nitroreductase for Improved Activation of Prodrugs and PET Probes for Cancer Gene Therapy.

J. Smaill, J. Flanagan, J. Copp, 2017, Cell chemical biology.

A phase I pharmacokinetic study of PR-104, a hypoxia-targeting agent, in patients with solid tumors

W. Denny, W. Wilson, J. Gutheil, 2007 .

Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine.

W. Wilson, K. Patel, K. Hicks, 2007, International journal of radiation oncology, biology, physics.

A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells.

S. Bohlander, M. Konopleva, W. Wilson, 2014, Biochemical pharmacology.

Characterization of radicals formed following enzymatic reduction of 3-substituted analogues of the hypoxia-selective cytotoxin 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).

W. Denny, R. Anderson, M. Hay, 2010, Journal of the American Chemical Society.

Bystander Effects of Bioreductive Drugs: Potential for Exploiting Pathological Tumor Hypoxia with Dinitrobenzamide Mustards

W. Wilson, N. Helsby, K. Hicks, 2007, Radiation research.

Structure−Activity Relationships of 1,2,4-Benzotriazine 1,4-Dioxides as Hypoxia-Selective Analogues of Tirapazamine

S. Gamage, W. Denny, W. Wilson, 2003 .

Subcellular Location of Tirapazamine Reduction Dramatically Affects Aerobic but Not Anoxic Cytotoxicity

Su Jung Lee, W. Denny, W. Wilson, 2020, Molecules.

Characterisation of radicals formed by the triazine 1,4-dioxide hypoxia-activated prodrug, SN30000.

W. Denny, J. Reynisson, R. Anderson, 2014, Organic & biomolecular chemistry.

Spin trapping of radicals other than the *OH radical upon reduction of the anticancer agent tirapazamine by cytochrome P450 reductase.

M. Hay, A. Patterson, S. S. Shinde, 2009, Journal of the American Chemical Society.

Radiolytic and cellular reduction of a novel hypoxia-activated cobalt(III) prodrug of a chloromethylbenzindoline DNA minor groove alkylator.

W. Wilson, G. Ahn, M. Tercel, 2006, Biochemical pharmacology.

Design, Synthesis and In-Vitro Biological Evaluation of Antofine and Tylophorine Prodrugs as Hypoxia-Targeted Anticancer Agents

J. Smaill, P. Fischer, Ashraf N. Abdalla, 2021, Molecules.

Advances in Brief Thymidine Phosphorylase Moderates Thymidine-dependent Rescue after Exposure to the Thymidylate Synthase Inhibitor ZD 1694 ( Tomudex ) in Vitro

D. Talbot, I. Stratford, Adrián, 2006 .

Mechanism of Action and Preclinical Antitumor Activity of the Novel Hypoxia-Activated DNA Cross-Linking Agent PR-104

Rachelle S. Singleton, W. Denny, W. Wilson, 2007, Clinical Cancer Research.

Alanine scan-guided synthesis and biological evaluation of analogues of culicinin D, a potent anticancer peptaibol.

J. Smaill, M. Brimble, P. Harris, 2020, Bioorganic & medicinal chemistry letters.

Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A

W. Wilson, L. Thompson, G. Atwell, 2009, Molecular Cancer Therapeutics.

DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity.

Rachelle S. Singleton, W. Wilson, M. Dorie, 2009, Cancer research.

Chinese Journal of Cancer

Dong-hai Wu, J. Smaill, K. Ding, 2022 .

Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice

W. Wilson, Xueying Sun, K. Patel, 2011, Cancer Chemotherapy and Pharmacology.

Targeted mutagenesis of the Vibrio fischeri flavin reductase FRase I to improve activation of the anticancer prodrug CB1954.

J. Smaill, J. Copp, D. Ackerley, 2012, Biochemical pharmacology.

uvrB gene deletion enhances SOS chromotest sensitivity for nitroreductases that preferentially generate the 4-hydroxylamine metabolite of the anti-cancer prodrug CB1954.

G. Prosser, D. Ackerley, A. Patterson, 2010, Journal of biotechnology.

Pre-Clinical Activity of Novel Hypoxia-Activated FLT3 Inhibitors in FLT3-Mutated AML

M. Konopleva, J. Smaill, N. Daver, 2016 .

ICTR 2003 Translational Research and Pre-Clinical Strategy Study THE BIOREDUCTIVE AGENT RH1 AND -IRRADIATION BOTH CAUSE G2/M CELL CYCLE PHASE ARREST AND POLYPLOIDY IN A p53-MUTATED HUMAN BREAST CANCER CELL LINE

J. Hendry, I. Stratford, J. Y. Kim, 2004 .

Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials

P. Lambin, L. Dubois, D. de Ruysscher, 2019, Clinical and translational radiation oncology.

Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer.

Cheng Zhang, Ke Ding, Donghai Wu, 2018, European journal of medicinal chemistry.

Abstract 4025: STEAP4 ISH and IHC diagnostics for Tarloxotinib activation in EGFR/HER2 mutant cancers

F. Hirsch, R. Doebele, J. Smaill, 2019, Clinical Research (Excluding Clinical Trials).

Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours

R. Airley, B. Telfer, C. Wolf, 2002, Gene Therapy.

CANCER CHEMOTHERAPY AND DRUG METABOLISM

D. Waxman, E. Chinje, I. Stratford, 2005, Drug Metabolism and Disposition.

Symposium Report CANCER CHEMOTHERAPY AND DRUG METABOLISM

D. Waxman, E. Chinje, I. Stratford, 2005 .

Tissue Pharmacokinetic Properties and Bystander Potential of Hypoxia-Activated Prodrug CP-506 by Agent-Based Modelling

J. Smaill, K. Hicks, A. Patterson, 2022, Frontiers in Pharmacology.

Nitro-chloromethylbenzindolines: hypoxia-activated prodrugs of potent adenine N3 DNA minor groove alkylators

W. Wilson, F. Pruijn, H. Liyanage, 2009, Molecular Cancer Therapeutics.

Synthesis and Structure−Activity Relationships for 2,4-Dinitrobenzamide-5-mustards as Prodrugs for the Escherichia coli nfsB Nitroreductase in Gene Therapy

W. Denny, W. Wilson, G. Atwell, 2007 .

Bioreductive prodrug PR-104 improves the tumour distribution and titre of the nitroreductase-armed oncolytic adenovirus ONYX-411NTR leading to therapeutic benefit

W. Wilson, J. Smaill, D. Singleton, 2021, Cancer Gene Therapy.

Bioreductive prodrug PR-104 improves the tumour distribution and titre of the nitroreductase-armed oncolytic adenovirus ONYX-411NTR leading to therapeutic benefit

W. Wilson, J. Smaill, Dan Li, 2021, Cancer Gene Therapy.

Design, Synthesis, and Biological Evaluation of Aminoindazole Derivatives as Highly Selective Covalent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR4.

J. Smaill, Yongheng Chen, Xiaoyun Lu, 2022, Journal of medicinal chemistry.

Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix.

R. Airley, I. Stratford, C. West, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Structural Mechanism and Inhibitors Targeting EGFR Exon 20 Insertion (Ex20ins) Mutations.

J. Smaill, Hao Chen, A. Patterson, 2023, Journal of medicinal chemistry.

Fourth-Generation Analogues of the Anticancer Peptaibol Culicinin D: Probing the Effects of Hydrophobicity and Halogenation on Cytotoxicity

J. Smaill, M. Brimble, P. Harris, 2021, Synthesis.

Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed.

J. Smaill, J. Flanagan, M. McKeage, 2015, Journal of structural biology.

The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3.

Rachelle S. Singleton, S. Fox, W. Wilson, 2010, Cancer research.

Engineering Escherichia coli NfsB to activate a hypoxia-resistant analog of the PET probe EF5 to enable non-invasive imaging during enzyme-prodrug therapy.

J. Smaill, J. Flanagan, J. Copp, 2019, Biochemistry.

Clostridium Bacteria: Harnessing Tumour Necrosis for Targeted Gene Delivery

J. Theys, A. Patterson, Alexsandra Mowday, 2024, Molecular diagnosis & therapy.

Discovery of 6-Formylpyridyl Urea Derivatives as Potent Reversible-Covalent Fibroblast Growth Factor Receptor 4 Inhibitors with Improved Anti-Hepatocellular Carcinoma Activity.

J. Smaill, A. Patterson, Xiaojuan Chen, 2024, Journal of medicinal chemistry.

A phase I pharmacokinetic study of PR-104, a hypoxia-activated nitrogen mustard prodrug, in patients with solid tumors

W. Denny, W. Wilson, J. Gutheil, 2008 .

Toward a high-throughput screening platform for directed evolution of enzymes that activate genotoxic prodrugs.

J. Smaill, J. Copp, M. Rich, 2014, Protein engineering, design & selection : PEDS.

Abstract A157: Antitumor activity of tarloxotinib, a hypoxia-activated EGFR TKI, in patient-derived lung cancer cell lines harboring EGFR exon 20 insertions

R. Doebele, J. Smaill, A. Le, 2018 .

The importance of DT-diaphorase and hypoxia in the cytotoxicity of RH1 in human breast and non-small cell lung cancer cell lines

I. Stratford, A. Patterson, J. Hendry, 2004, Anti-cancer drugs.

FGFR4 complex with N-(3-chloro-2-((5-((2,6-dichloro-3,5-dimethoxybenzyl)oxy)pyrimidin-2-yl)amino)-5-fluorophenyl)acrylamide

J. Smaill, Xiaoyun Lu, A. Patterson, 2019 .

Tumor-targeting bacteria as immune stimulants – the future of cancer immunotherapy?

J. Theys, K. Henare, A. Patterson, 2024, Critical reviews in microbiology.

Spin trapping of radicals other than the *OH radical upon reduction of the anticancer agent tirapazamine by cytochrome P450 reductase.

W. Denny, M. Hay, A. Patterson, 2009, Journal of the American Chemical Society.

Cytotoxicity of the bioreductive agent RH1 and its lack of interaction with radiation.

J. Hendry, S. Roberts, T. Ward, 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

The relative importance of NADPH: cytochrome c (P450) reductase for determining the sensitivity of human tumour cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions.

A. Harris, A. Patterson, I. Stratford, 2000, Biochemical pharmacology.